Avenue Therapeutics News

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the

GlobeNewswireJun 20 08:30 ET

Maxim Group Maintains Avenue Therapeutics(ATXI.US) With Buy Rating

Maxim Group analyst Jason McCarthy maintains $Avenue Therapeutics(ATXI.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 29.1% and a total average return of -16.8% o

moomoo NewsJun 7 12:31 ET · Ratings

Express News | Avenue Therapeutics Inc : Maxim Group Cuts Target Price to $12 From $56.25 to Reflect 1-for-75 Reverse Stock Split

ReutersJun 7 00:12 ET

Express News | Avenue Therapeutics: Received Notice From Nasdaq Notifying Co Is in Compliance With All Requirement Set Forth in Nasdaq Listing Rule 5550(B)(1)

ReutersMay 23 08:34 ET

Express News | Avenue Therapeutics Completes Last Patient Last Visit In Phase 1b/2a Clinical Trial Of AJ201 For Spinal And Bulbar Muscular Atrophy

BenzingaMay 16 08:32 ET

Express News | Avenue Therapeutics Inc - Topline Data Are Expected to Be Reported Mid-Year 2024

ReutersMay 16 08:30 ET

Express News | Avenue Therapeutics Inc - Announced Completion of Last Patient's Final Visit in Company's Phase 1B/2a Clinical Trial of AJ201

ReutersMay 16 08:30 ET

Express News | Avenue Therapeutics Announces Last Patient Last Visit in Phase 1B/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

ReutersMay 16 08:30 ET

Avenue Therapeutics | 10-Q: Quarterly report

SEC announcementMay 15 16:26 ET · Announcements

Express News | Avenue Therapeutics Inc - Qtrly Shr Loss $15.40

ReutersMay 15 08:32 ET

Avenue Therapeutics 1Q Loss/Shr $15.40 >ATXI

Avenue Therapeutics 1Q Loss/Shr $15.40 >ATXI

Dow JonesMay 15 08:31 ET

Express News | Avenue Therapeutics May Offer Shares Of Common Stock Having Offering Price Of Up To $3.9M From Time To Time Through Agent

BenzingaMay 10 16:56 ET

Express News | Avenue Therapeutics Inc: May Offer Shares of Common Stock Having Offering Price of up to $3.9 Mln From Time to Time Through Agent

ReutersMay 10 16:55 ET

Avenue Therapeutics Files to Sell 1.42M Shares

Seeking AlphaMay 6 15:14 ET

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it

BenzingaApr 29 13:04 ET

FLGC, BTOG and CAUD Among Mid-day Movers

Seeking AlphaApr 29 12:31 ET

Why Avenue Therapeutics (ATXI) Stock Is Falling Sharply

Avenue Therapeutics (NASDAQ:ATXI) shares are trading lower by 20.7% to $4.92 during Monday's session after the company announced the exercise of warrants for $4.4 million in gross proceeds.These warra

BenzingaApr 29 10:59 ET

ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings Among Healthcare Movers

Seeking AlphaApr 29 10:02 ET

Express News | Avenue Therapeutics Shares Are Trading Lower After the Company Announced the Exercise of Warrants for $4.4 Million in Gross Proceeds

BenzingaApr 29 09:04 ET

Express News | Avenue Therapeutics Announces Exercise of Warrants For $4.4M In Gross Proceeds

BenzingaApr 29 08:14 ET